Darwin Platform Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-12-2024
- Paid Up Capital ₹ 0.50 M
as on 16-12-2024
- Company Age 12 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 Cr
as on 16-12-2024
- Revenue 85.33%
(FY 2020)
- Profit -54.66%
(FY 2020)
- Ebitda -38.72%
(FY 2020)
- Net Worth 0.01%
(FY 2020)
- Total Assets 0.03%
(FY 2020)
About Darwin Platform Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.00 Cr.
Manoj Pincha, Herambha Naik, Rahul Dhote, and One other member serve as directors at the Company.
- CIN/LLPIN
U85191MH2012PLC235261
- Company No.
235261
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
03 Sep 2012
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Darwin Platform Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Pincha  | Additional Director | 23-Apr-2024 | Current |
| Herambha Naik | Director | 29-Sep-2015 | Current |
| Rahul Dhote | Director | 05-Mar-2020 | Current |
| Vasu Kumar | Director | 11-Jun-2021 | Current |
Financial Performance and Corporate Structure Insights of Darwin Platform Pharmaceuticals.
Darwin Platform Pharmaceuticals Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 85.33% increase. The company also saw a substantial fall in profitability, with a 54.66% decrease in profit. The company's net worth moved up by a moderate rise of 0.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Darwin Platform Pharmaceuticals?
In 2020, Darwin Platform Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Darwin Platform1 News LimitedActive 12 years 6 monthsHerambha Naik and Vasu Kumar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 23 Jun 2023 | ₹5.00 Cr | Open |
How Many Employees Work at Darwin Platform Pharmaceuticals?
Darwin Platform Pharmaceuticals has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Darwin Platform Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Darwin Platform Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
